[Standard heparin versus low-molecular-weight heparin].

Area of Science:

• Vascular Medicine
• Pharmacology
• Thrombosis Research

Background:

• Deep vein thrombosis (DVT) is a significant vascular condition.
• Standard heparin therapy (UFH) is effective but requires careful monitoring.
• Alternative anticoagulants are being investigated for improved efficacy and patient convenience.

Purpose of the Study:

• To compare the efficacy and safety of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) in treating leg deep vein thromboses.
• To evaluate the impact of LMWH on thromboembolic recurrence, thrombus extension, bleeding events, and mortality.
• To assess the cost-effectiveness and patient convenience of LMWH therapy.

Main Methods:

• Comparative study of LMWH and UFH in DVT patients.
• Monitoring of clinical outcomes including recurrent thrombosis, bleeding complications, and mortality.
• Analysis of treatment administration methods (outpatient vs. inpatient) and associated costs.

Main Results:

• LMWH demonstrated significantly lower rates of thromboembolic recurrence and thrombus extension compared to UFH.
• Fewer bleeding events and reduced mortality were observed in the LMWH group.
• LMWH allows for subcutaneous administration, facilitating outpatient treatment and reducing overall treatment costs by approximately 50%.

Conclusions:

• Low molecular weight heparin (LMWH) is a safe and effective alternative to unfractionated heparin (UFH) for treating deep vein thrombosis.
• The outpatient administration of LMWH improves patient convenience and significantly lowers treatment costs.
• While differences in clinical outcomes are small, the practical advantages of LMWH support its use in DVT management.